Press Release October 17, 2017

Gemini Therapeutics Completes $42.5 Million Series A Financing

Goodwin’s Life Sciences team advised Gemini Therapeutics on the completion of its $42.5 million Series A financing round to advance multiple programs into the clinic. Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A, and also invested in seed financing in 2016. Gemini is developing first-in-class therapeutics built on the strong foundation of human genetics research in age-related macular degeneration (AMD), the leading cause of irreversible blindness in the U.S. and EU.

Gemini Therapeutics is a precision medicine company focused on genetically defined dry AMD and associated rare genetic diseases.

The Goodwin team was led by partners Mitchell Bloom and Laurie Burlingame and included counsel Kathleen Kean, and associates Patricia Mets and Sarah Smith.